{"id":222891,"date":"2026-04-20T13:55:11","date_gmt":"2026-04-20T13:55:11","guid":{"rendered":"https:\/\/www.europesays.com\/se\/222891\/"},"modified":"2026-04-20T13:55:11","modified_gmt":"2026-04-20T13:55:11","slug":"kvinnor-gar-ner-mer-i-vikt-av-glp-1-lakemedel-an-man","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/222891\/","title":{"rendered":"Kvinnor g\u00e5r ner mer i vikt av GLP-1-l\u00e4kemedel \u00e4n m\u00e4n"},"content":{"rendered":"<p>En omfattande forskningsanalys publicerad i\u00a0<a href=\"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/article-abstract\/2845663\" rel=\"nofollow noopener\" target=\"_blank\">JAMA Internal Medicine<\/a>\u00a0visar att\u00a0GLP-1-analoger, mot fetma och diabetes, generellt \u00e4r\u00a0mer effektiva f\u00f6r kvinnor\u00a0\u00e4n f\u00f6r m\u00e4n. De l\u00e4kemedel som ingick i studien var bland annat semaglutid, liraglutid, exenatid, lixisenatid och dulaglutid.<\/p>\n<p>Kvinnor g\u00e5r i genomsnitt ned i vikt 11 procent<\/p>\n<p>Genom att granska ett stort antal kliniska studier fann forskarna att kvinnor i genomsnitt uppn\u00e5dde en\u00a0viktminskning p\u00e5 elva procent, medan motsvarande siffra f\u00f6r m\u00e4n stannade vid sju procent.<\/p>\n<p>Skillnaden i resultat kan eventuellt f\u00f6rklaras av l\u00e4kemedlens interaktion med\u00a0\u00f6strogen\u00a0eller variationer i hur kroppar av olika k\u00f6n bearbetar substanserna.<\/p>\n<p>Effekten konsekvent oavsett \u00e5lder<\/p>\n<p>Samtidigt understryker studien att medicinernas effekt \u00e4r\u00a0konsekvent och likv\u00e4rdig\u00a0oavsett patientens \u00e5lder, etniska bakgrund eller ursprungliga kroppsmasseindex. Dessa r\u00f6n kan ge ett b\u00e4ttre underlag f\u00f6r att f\u00f6rutse behandlingsresultat och\u00a0anpassa v\u00e5rden\u00a0f\u00f6r olika patientgrupper.<\/p>\n","protected":false},"excerpt":{"rendered":"En omfattande forskningsanalys publicerad i\u00a0JAMA Internal Medicine\u00a0visar att\u00a0GLP-1-analoger, mot fetma och diabetes, generellt \u00e4r\u00a0mer effektiva f\u00f6r kvinnor\u00a0\u00e4n f\u00f6r&hellip;\n","protected":false},"author":2,"featured_media":222892,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[69],"tags":[14647,15738,113,112,10225,13301,34,2653,31,33,32,30],"class_list":["post-222891","post","type-post","status-publish","format-standard","has-post-thumbnail","category-halsa","tag-diabeteslakemedel","tag-glp-1","tag-halsa","tag-health","tag-obesitas","tag-obesitaslakemedel","tag-se","tag-semaglutid","tag-svenska","tag-sverige","tag-sweden","tag-swedish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/116437380657580924","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/222891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=222891"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/222891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/222892"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=222891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=222891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=222891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}